NCT02438215View on ClinicalTrials.gov

Study of IRX4204 for Treatment of Early Parkinson's Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions

Parkinson's Disease

Interventions

DRUG

IRX4204

IRX4204 is a potent and highly selective orally available and brain penetrant RXR nuclear receptor agonist small compound administered as gel capsules.

Trial Locations (1)

06510

Molecular NeuroImaging, [MNI], New Haven